Clinical Trials

Leukemia, Myeloid, Acute

NCT04195945 2026-05-14

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients

60 enrolled 19 charts

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute

NCT04801797 2026-05-12

Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

172 enrolled

Phase 1 Active not recruiting

Leukemia, Myeloid, Acute

NCT05453903 2026-05-08

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

196 enrolled

Leukemia, Myeloid, Acute

NCT06497062 2026-04-30

Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia

47 enrolled

Leukemia, Myeloid, Acute

NCT01627041 2026-04-27

Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia

178 enrolled

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Myelomonocytic, Acute

NCT03591510 2026-04-27

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

22 enrolled

Leukemia, Myeloid, Acute

NCT03164057 2026-04-23

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

206 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04214249 2026-04-13

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

49 enrolled 32 charts

Leukemia, Myeloid, Acute

NCT04231851 2026-03-06

CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

30 enrolled 15 charts

Leukemia, Myeloid, Acute

NCT05656248 2026-02-04

Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms

25 enrolled

Phase 2/3 Active not recruiting

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Juvenile

NCT03701308 2026-01-21

Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

267 enrolled 11 charts

Phase 1 Active not recruiting

Leukemia, Myeloid, Acute

NCT03709758 2026-01-16

Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML

50 enrolled

Leukemia, Myeloid, Acute

NCT04802161 2025-12-19

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

50 enrolled 12 charts

Phase 3 Active not recruiting

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT01371981 2025-11-26

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

1,645 enrolled 32 charts

Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT04817241 2025-11-10

Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients

Phase 1/2 Active not recruiting

5 enrolled

Phase 3 Active not recruiting

Leukemia, Myeloid, Acute

NCT02521493 2025-08-01

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

280 enrolled 13 charts

Phase 3 Active not recruiting

Down Syndrome, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT03897127 2025-07-17

Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics

882 enrolled

Leukemia, Myeloid, Acute

NCT03836209 2025-06-15

Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

181 enrolled 18 charts